Brain Tumor News!


Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!
Displaying Stories 2141 to 2160 of 7,674
Previous 20           Next 20


03/27/14 The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors        

 It sounds exciting, and the best part is they will be trying it for many types of cancers, so they should be able to get funding for it.  It is really hard to raise money to test things like this for brain cancer alone.



03/24/14 The Amazon Smile Foundation will donate an extra $5 to the Musella Foundation for each shopper!        

If you use Amazon, please follow the directions in this article... and you can generate donations to us without it costing you anything extra!



03/24/14 Changes to the Musella Foundation Website: "Clinical Trials And Noteworthy Treatments For Brain Tumors"        

 Let me know what you think of the changes and if you have any ideas for improvements!



03/22/14 FDA agrees to let patients get controversial drug        

 I have mixed feelings on this one. On the one hand, I am all for patients being allowed to try experimental treatments, especially when all approved options have run out and they are not eligible for clinical trials.  On the other hand, some protection of the patient is needed.

I would propose a few things before I allowed this to be made available:

1. Release all of the data on the clinical trials that have been run.  They have not been published. Unofficial sources have said that there were over 100 trials of this treatment, and 99 of them showed negative results. 1 showed good results.  Statistically, at the level of proof most commonly used, .05%, if you ran 100 trials, you would expect 5 of them to come out positive by chance alone.  Having only 1 positive and 99 negative trials leads me to believe this is not the miracle drug it is touted to be.

2. I understand a traditional clinical trial can not be run on this group of patients, however, that does not mean that their experiances should go to waste.  All patients who use a compassionate use treatment should be tracked.  Our "Brain tumor virtual trial" is a perfect vehicle for this.   An individual success is meaningless.  About 10% of kids and a higher % of adults with brainstem gliomas do well for a long time on the standard treatments. If you take 3 patients, there is a good chance that 1 of them, and a small chance that 2 or 3 of them, would do well no matter what you did to them. However, if you had 50 patients tracked from before they start the treatment, the chances that 25 of them do well is pretty low if the treatment is not working.  Not as convincing proof as a randomized blinded trial, but good enough for me and the people who have no other options. 



03/21/14 Vulnerability of Glioblastoma Cells to Catastrophic Vacuolization and Death Induced by a Small Molecule        

 Interesting new approach. Too early - only in mice now, but it looks like something to keep an eye on.



03/19/14 IBM’s Watson, New York Genome Center partner on brain cancer treatment        

 I love this.  It would be a perfect tool to use with our brain tumor virtual trial!



03/19/14 Methods for the detection of cytomegalovirus in glioblastoma cells and tissues.        

 This is a controversial area. Some centers find cytomegalovirus in all GBM cells, other centers can't find it at all. This is an attempt to standardize the procedure for looking for the virus.  Hopefully, this will allow all labs to confirm that the virus is present in a very high number of gbm cells



03/18/14 First Patient Enrolled in GenSpera G-202 Phase II Glioblastoma Trial        

 Sounds like an interesting trial.



03/18/14 Hoops for Hannah college basketball contest.        

 This is a fun fundraiser that anyone can participate in from their own home.  The deadline is  this Thursday - so do it now if you are interested!  



03/16/14 Doctors decode chemo resistance in childhood brain tumour, find potential drug        

They may have found a better treatment for ependymomas in kids.  I usually say it is too early, since they didn't do the clinical trials yet, but when you have no other treatment, this may make sense. It is a drug approved for a different type of cancer so is easy to get.



03/13/14 Small But Fierce: Four Funders Come Together for Brain Tumor Research        

 We are  one of the organizations mentioned!



03/13/14 IBTA E-NEWS        

 Form our friends at the IBTA



03/13/14 Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy        

We still do not know the best way to use Avastin. This articles seems to say that it doesn't matter when you start it - at the start, after first, second or third recurrence.  It still gives about the same effect.



03/12/14 Musella Foundation Copay Assist program is now closed!        

 We have used up our funding and can no longer accept new applications.  



03/12/14 http://phys.org/wire-news/156012592/aacr-recognizes-contributions-of-multi-institutional-research-te.html        

 It's nice to see these top researchers to get the recognition they deserve!



03/11/14 Exclusive: Germany OKs Northwest Bio brain cancer drug, shares soar        

 Great news!  DC-Vax can now be sold in Germany.  I do not know yet if Americans can go get it and bring it back. If anyone tries, please let me know how it goes.



03/11/14 Tocagen Doses First Patient Intravenously in Clinical Trial of Selective Cancer Therapy, Toca 511 & Toca FC        

 The Toca 511 trial has been one of my favorites. It is a new type of gene therapy where a virus that only grows in tumor cells delivers a gene that can convert an oral  nontoxic antifungal drug into a powerful chemotherapy, only in the cancer cells that were infected by the virus.  There are now 3 separate clinical trials going on for the Tocagen treatment.  The original 2 used local delivery of the virus to the area of the tumor. This one adds an IV injection of the virus and also local delivery. The idea is that it may be better able to hit those tumor cells that are spread out in the brain, far from where the MRI says the tumor is.

The Musella Foundation is one of the sponsors!



03/08/14 Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma.        

  It is too early to tell if it would help people with gbms, but the best thing is that the drugs are already approved, so if the trial looks good,  we can use these off label  quickly!



03/08/14 Implications of bevacizumab (Avastin) discontinuation in adults with recurrent glioblastoma.        

 This article looked at GBM patients  who took Avastin for longer than 6 months and then discontinued it.  1/4 of the patients stopped for reasons other than tumor progression, and 3/4 stopped because of tumor progression. Then they analysed what happened, looking for a "theoretical" rebound effect. They didn't find it. Those who stopped because of other reasons did a lot better than those who stopped because of progression.



03/07/14 NW Bio Receives Recommendation To Continue With Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board's Safety Review        

 Great news! The DC-Vax trial passed it's  safety review and can continue without changes.  Of course, that is what we expected but it is great to hear!  Good luck to the trial! 



Displaying Stories 2141 to 2160 of 7674
Previous 20           Next 20